Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1  von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J. Cachexia Sarcopenia Muscle1(1),1–5 (2010).
  MedlineGoogle Scholar
• 2  Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol.12(5),489–495 (2011).•• Describes the latest international consensus on the framework for the definition and classification of cancer cachexia, which upon validation should aid clinical trial design, development of practice guidelines and routine clinical management.
  MedlineGoogle Scholar
• 3  Kumar NB, Kazi A, Smith T et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr. Treat. Options Oncol.11(3–4),107–117 (2010).
  MedlineGoogle Scholar
• 4  Suzuki H, Asakawa A, Amitani H, Fujitsuka N, Nakamura N, Inui A. Cancer cachexia pathophysiology and translational aspect of herbal medicine. Jpn. J. Clin. Oncol.43(7),695–705 (2013).
  MedlineGoogle Scholar
• 5  Dodson S, Baracos VE, Jatoi A et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu. Rev. Med.62,265–279 (2011).
  Medline CASGoogle Scholar
• 6  Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol.10(2),90–99 (2013).
  Medline CASGoogle Scholar
• 7  Ross PJ, Ashley S, Norton A et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br. J. Cancer.90(10),1905–1911 (2004).
  Medline CASGoogle Scholar
• 8  August DA, Huhmann MB; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. J.P.E.N. J. Parenter. Enteral. Nutr.33(5),472–500 (2009).
  MedlineGoogle Scholar
• 9  Leśniak W, Bala M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Pol. Arch. Med. Wewn.118(11),636–644 (2008).
  Medline CASGoogle Scholar
• 10  Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev.3,CD004310 (2013).
  MedlineGoogle Scholar
• 11  Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database Syst. Rev.4,CD008664 (2012).
  MedlineGoogle Scholar
• 12  Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated Fatty acids in the management of symptoms, survival, and quality of life. J. Pain Symptom Manage.37(6),1069–1077 (2009).
  Medline CASGoogle Scholar
• 13  Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev.1,CD004597 (2007).
  MedlineGoogle Scholar
• 14  Bhattacharyya GS, Julka PK, Bondarde S et al. Phase II study evaluating safety and efficacy of coadministering propranolol and etodolac for treating cancer cachexia. J. Clin. Oncol.28(Suppl.),e18059 (2010).
  Google Scholar
• 15  Reichert JM. Antibodies to watch in 2013: mid-year update. MAbs5(4),513–517 (2013).
  MedlineGoogle Scholar
• 16  Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J. Am. Med. Dir. Assoc.12(1),62–67 (2011).
  MedlineGoogle Scholar
• 17  Dobs AS, Boccia RV, Croot CC et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled Phase 2 trial. Lancet Oncol.14(4),335–345 (2013).
  Medline CASGoogle Scholar
• 18  Crawford J, Dalton JT, Hancock ML et al. Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC. Eur. J. Cancer49(Suppl. 2),LBA21 (2013).
  Google Scholar
• 19  Mantovani G, Madeddu C, Macciò A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Des. Devel. Ther.7,645–656 (2013).
  MedlineGoogle Scholar
• 20  Stewart Coats AJ, Srinivasan V, Surendran J et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J. Cachexia Sarcopenia Muscle.2(4),201–207 (2011).
  MedlineGoogle Scholar
• 21  Aydin S, Sahin I, Ozkan Y et al. Examination of the tissue ghrelin expression of rats with diet-induced obesity using radioimmunoassay and immunohistochemical methods. Mol. Cell Biochem.365(1–2),165–173 (2012).
  Medline CASGoogle Scholar
• 22  Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH. Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol.31(1),44–60 (2010).
  Medline CASGoogle Scholar
• 23  Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell132,387–396 (2008).
  Medline CASGoogle Scholar
• 24  Gutierrez JA, Solenberg PJ, Perkins DR et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc. Natl Acad. Sci. USA105,6320–6325 (2008).
  Medline CASGoogle Scholar
• 25  Li L, Zhang LK, Pang YZ et al. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol. Sin.27(5),527–535 (2006).
  MedlineGoogle Scholar
• 26  Delhanty PJ, Sun Y, Visser JA et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE5(7),e11749 (2010).
  MedlineGoogle Scholar
• 27  Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762),656–660 (1999).
  Medline CASGoogle Scholar
• 28  Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature409(6817),194–198 (2001).
  Medline CASGoogle Scholar
• 29  Wang W, Andersson M, Iresjö BM, Lönnroth C, Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int. J. Oncol.28(6),1393–1400 (2006).
  Medline CASGoogle Scholar
• 30  DeBoer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology148(6),3004–3012 (2007).
  Medline CASGoogle Scholar
• 31  Neary NM, Small CJ, Wren AM et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.89(6),2832–2836 (2004).
  Medline CASGoogle Scholar
• 32  Pietra C, Takeda Y, Tazawa-Ogata N et al. The preclinical pharmacological profile of anamorelin/ONO-7643, a new ghrelin receptor agonist for the treatment of cancer cachexia. Ann. Oncol.23(Suppl. 9),ix499–ix527 (2012) (Abstract 465P).
  Google Scholar
• 33  Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J. Biol. Chem.278(1),64–70 (2003).
  Medline CASGoogle Scholar
• 34  Northrup R, Kuroda K, Duus EM et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer21(9),2409–2415 (2013).• Preclinical study in nude mice with established A549 tumors, demonstrating that mean body weight significantly increased in anamorelin-administered mice, and that neither anamorelin nor ghrelin promoted tumor growth.
  Medline CASGoogle Scholar
• 35  Blum R, Polvino W. Pharmacokinetic (PK) profile of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia/cachexia. Support. Care Cancer14,583–687 (2006) (Abstract 03-010).
  Google Scholar
• 36  Kumor K, Polvino W. Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia/cachexia: results from a Phase I randomized, double-blind, placebo-controlled trial in healthy volunteers. Support. Care Cancer14,583–687 (2006) (Abstract 03-009).
  Google Scholar
• 37  Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a Phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist.12(5),594–600 (2007).• Phase I study of anamorelin in healthy volunteers showing dose-related increases in body weight with no dose-limiting adverse events.
  Medline CASGoogle Scholar
• 38  Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm. IGF Res.19(3),267–273 (2009).• Phase I study focusing on the evaluation of the short-term effects of anamorelin on growth hormone, IGF-1, IGFBP-3, other pituitary hormones and glucose. Results show that anamorelin significantly increased growth hormone levels and positive changes in body weight directly correlated with changes in IGF-1 levels.
  Medline CASGoogle Scholar
• 39  Garcia J, Boccia RV, Graham C, Kumor K, Polvino W. A Phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J. Clin. Oncol.18(Suppl.),9133 (2007).
  Google Scholar
• 40  Garcia JM, Yan Y, Duus E, Friend J. Anamorelin’s effects on appendicular lean body mass in cancer patients with cachexia: results from a Phase II randomized, double blind, multicenter study. Ann. Oncol.23(Suppl. 9),ix499–ix527 (2012) (Abstract 1588P).
  Google Scholar
• 41  Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer21(1),129–137 (2013).•• Important Phase II study evaluating the effects of anamorelin in 16 patients with different cancers and cachexia. Results show that anamorelin has significant metabolic, clinical and patient-rated effects.
  MedlineGoogle Scholar
• 42  Lu M, Zabbatino SM, Garcia JM, Manning Duus E, Friend J. Anamorelin’s effect on bone mass: beyond the expected outcomes in non-small cell lung (NSCLC) cancer cachexia. Eur. J. Cancer49(Suppl. 2),1316 (2013).
  Google Scholar
• 43  Abernethy AP, Temel JS, Currow D et al. Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia. J. Clin. Oncol.31(Suppl.),TPS9649 (2013).
  Google Scholar
• 44  Newman AB, Kupelian V, Visser M et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci.61(1),72–77 (2006).
  MedlineGoogle Scholar
• 101  National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Palliative Care 2013. www.nccn.org/professionals/physician_gls/pdf/palliative.pdf (Accessed 14 November 2013).
  Google Scholar
• 102  European Palliative Care Research Collaborative. European Clinical Guidelines: Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia 2010. www.epcrc.org/guidelines.php?p=cachexia (Accessed 14 November 2013).
  Google Scholar
• 103  ClinicalTrials.gov. Pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. http://clinicaltrials.gov/ct2/show/NCT01614990 (Accessed 14 November 2013).
  Google Scholar
• 104  Ghrelin (Human). ChemicalBook.com. www.chemicalbook.com/ChemicalProductProperty_EN_CB1240638.htm
  Google Scholar
• 105  Temel J, Bondarde S, Jain M, Allen S, Mann W. Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter Phase II study. European Cancer Congress. Amsterdam, The Netherlands, 1308 (2013). www.poster-submission.com/board (Accessed 14 November 2013).
  Google Scholar
• 106  Garcia JM, Yan Y, Duus E, Friend J. Anamorelin’s effects on appendicular lean body mass in cancer patients with cachexia: results from a Phase II randomized, double blind, multicenter study. European Society for Medical Oncology Congress. Vienna, Austria, 1588 (2012). www.poster-submission.com/search/select/33 (Accessed 14 November 2013).
  Google Scholar
• 107  ClinicalTrials.gov. Safety and efficacy of anamorelin HCl in patients with non-small cell lung cancer-cachexia (ROMANA 1). http://clinicaltrials.gov/ct2/show/NCT01387269 (Accessed 14 November 2013).
  Google Scholar
• 108  ClinicalTrials.gov. Safety and efficacy of anamorelin HCl in patients with non-small cell lung cancer-cachexia (ROMANA 2). http://clinicaltrials.gov/ct2/show/NCT01387282 (Accessed 14 November 2013).
  Google Scholar
• 109  ClinicalTrials.gov. Anamorelin HCl in the treatment of non-small cell lung cancer-cachexia (NSCLC-C): an extension study (ROMANA 3). http://clinicaltrials.gov/ct2/show/NCT01395914 (Accessed 14 November 2013).
  Google Scholar